Pharmacotherapy for Obesity—Trends Using a Population Level National Database

Elangovan, Abbinaya; Shah, Raj; Smith, Zachary L.

doi:10.1007/s11695-020-04987-2

Cited by 29 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, five drugs have been approved by the U.S. Food and Drug Administration (FDA) as anti‐obesity agents in patients with a body mass index (BMI) ≥27 kg/m 2 and at least one obesity‐related metabolic disorder or patients with BMI ≥30 kg/m 2 [6,7] . These drugs focus primarily on reducing energy intake by targeting pathways in the central nervous system (CNS) or preventing dietary fat absorption by inhibiting gastric and pancreatic lipases in the case of orlistat [8] .…”

Section: Introductionmentioning

confidence: 99%

Phenotypic Discovery of SB1501, an Anti‐obesity Agent, through Modulating Mitochondrial Activity

Kim

et al. 2021

ChemMedChem

View full text Add to dashboard Cite

Obesity has become a pandemic that threatens the quality of life and discovering novel therapeutic agents that can reverse obesity and obesity‐related metabolic disorders are necessary. Here, we aimed to identify new anti‐obesity agents using a phenotype‐based approach. We performed image‐based high‐content screening with a fluorogenic bioprobe (SF44), which visualizes cellular lipid droplets (LDs), to identify initial hit compounds. A structure‐activity relationship study led us to yield a bioactive compound SB1501, which reduces cellular LDs in 3T3‐L1 adipocytes without cytotoxicity. SB1501 induced the expression of gene products that regulate mitochondrial biogenesis and fatty acid oxidation in 3T3‐L1 adipocytes. Daily treatment with SB1501 improved the metabolic states of db/db mice by reducing body fat mass, adipose tissue mass, food intake, and increasing glucose tolerance. The anti‐obesity effect of SB1501 may result from perturbation of the PGC‐1α–UCP1 regulatory axis in inguinal white adipose tissue and brown adipose tissue. These data suggest the therapeutic potential of SB1501 as an anti‐obesity agent via modulating mitochondrial activities.

show abstract

Section: Introductionmentioning

confidence: 99%

Phenotypic Discovery of SB1501, an Anti‐obesity Agent, through Modulating Mitochondrial Activity

Kim

et al. 2021

ChemMedChem

View full text Add to dashboard Cite

show abstract

“…Use of antiobesity pharmacotherapy among the overall eligible population is quite low-estimates range from 1% to 2.4%; however, the proportion is increasing over time [30,41]. There are limited data to suggest that there are racial disparities in prescribing patterns for Black patients with obesity [42], as well as well-described racial disparities in the provision of other weight loss modalities and in representation in studies of weight loss interventions [43,44].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, diethylpropion, phendimetrazine, and benzphetamine were excluded from analysis as there is little clear FDA guidance about their use in the setting of kidney disease since their approval by the FDA six decades ago, and their use is limited. [30]…”

Section: What Does This Study Add?mentioning

confidence: 99%

Impact of refitted race‐free eGFR formula on obesity pharmacotherapy options

Orandi

McLeod

Reed

et al. 2022

Obesity

View full text Add to dashboard Cite

Objective: Recent changes to the Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate (eGFR) formula (2021 CKD-EPI) removed race from the 2009 formula, increasing the number of Black people classified as having CKD, but these changes may impact eligibility and/or dosing for antiobesity medications. This study estimated the number of people with obesity nationwide who might have pharmacotherapy options impacted by the new formula.Methods: Using National Health and Nutrition Examination Survey (NHANES) cohort study data, the number of people eligible for antiobesity medication was estimated, and the number who would require a dosage reduction or would no longer be eligible for specific medications based on the new eGFR formula was also estimated.

show abstract

“…These medications can reduce body weight by decreasing food consumption or absorption, or increasing energy expenditure [9]. During the last decade, most of the new generation of the AOMs have shown encouraging tolerability pro les with a modest increase in the prevalence of use [10]. However, the shortfall of prolonged follow-up may confound the accurate ascertainment of risk-bene t; many of the AOMs that were presented as the solution to obesity have been withdrawn from the market during the last two decades owing to reports of multiple major adverse events (AEs) associated with them [11].…”

Section: Introductionmentioning

confidence: 99%

Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020

et al. 2021

View full text Add to dashboard Cite

BackgroundObesity is a globally growing health problem, and its treatment has been challenging. The usage of antiobesity medications (AOMs) has been associated with severe adverse events (AEs). Spontaneous reports of AOMs can present detailed information about AEs occurring after the time of marketing. Several AOMs have been withdrawn from the market owing to documented AEs. ObjectiveTo estimate and characterize the frequency of AEs attributable to the use of the AOMs between January 2013 and June 2020.

show abstract

Pharmacotherapy for Obesity—Trends Using a Population Level National Database

Cited by 29 publications

References 43 publications

Phenotypic Discovery of SB1501, an Anti‐obesity Agent, through Modulating Mitochondrial Activity

Phenotypic Discovery of SB1501, an Anti‐obesity Agent, through Modulating Mitochondrial Activity

Impact of refitted race‐free eGFR formula on obesity pharmacotherapy options

Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020

Contact Info

Product

Resources

About